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Summary 
Attention deficit hyperactivity disorder (ADHD) is a common and challenging 
comorbidity affecting many children with epilepsy. A working group under the 
International League Against Epilepsy (ILAE) Pediatric Commission identified key 
questions on the identification and management of ADHD in children with epilepsy. 
Systematic reviews of the evidence to support approaches to these questions were 
collated and graded using criteria from the American Academy of Neurology Practice 
Parameter. PRISMA requirements were followed, with PROSPERO registration 
(CRD42018094617). 
No increased risk of ADHD in boys with epilepsy compared to girls with epilepsy was 
found (level A). Valproate use in pregnancy is associated with inattentiveness and 
hyperactivity in offspring (1 class I study), and children with intellectual and 
developmental disabilities are at increased risk of ADHD (level A). Impact of early 
seizure onset on development of ADHD was unclear (level U), but more evident with 
poor seizure control (level B). ADHD screening should be performed from 6 years of 
age, or at diagnosis, and repeated annually (level U) and reevaluated after change of 
antiepileptic drug (AED) (level U). Diagnosis should involve health practitioners with 
expert training in ADHD (level U). Use of the Strength and Difficulties Questionnaire 
screening tool is supported (level B). Formal cognitive testing is strongly 
recommended in children with epilepsy who are struggling at school (level U). 
Behavioral problems are more likely with polytherapy than monotherapy (level C). 
Valproate can exacerbate attentional issues in children with childhood absence 
epilepsy (level A). Methylphenidate is tolerated and effective in children with epilepsy 
(level B). Limited evidence supports that atomoxetine is tolerated (level C). 
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Multidisciplinary involvement in transition and adult ADHD clinics is essential (level 
U). 
In conclusion whilst recommendations could be proposed for some of the study 
questions, this systematic review highlighted the need for more comprehensive and 
targeted large population prospective studies.   
 
 
Key words: ADHD, Epilepsy, Children, AED, Screening tools, Methylphenidate  
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INTRODUCTION 
Epilepsy is a “spectrum” disorder, with associated cognitive and psychiatric 
impairment in approximately half of patients. Attention deficit hyperactivity disorder 
(ADHD), defined by DSM-5 Criteria as a persistent pattern of inattention and/or 
hyperactivity-impulsivity that interferes with functioning or development, is the most 
common comorbidity in children with epilepsy. 1, 2 Prevalence of ADHD in children 
with epilepsy is reported as 30-40% in targeted studies3-5 and 12.5-15% in a non-
targeted, population registry study,6 overall a rate 2.5 to 5.5 times higher than in 
otherwise healthy children without seizures. Attention problems often predate onset 
of seizures.6, 7 The predominantly inattentive type of ADHD is more prevalent in 
patients with epilepsy. 5, 9, 10 A large, population-based cohort study suggested that 
both genetic and environmental factors contribute to this comorbidity.7  
The impact of comorbid ADHD in people with epilepsy is significant, often 
associated with academic and vocational underachievement, depression and anxiety.8, 
9
 Furthermore, ADHD is under-diagnosed in children with epilepsy,10 as difficulties with 
attention and behavior are attributed to the epilepsy itself, or to effects of antiepileptic 
drugs (AEDs). Even if recognized, ADHD is frequently untreated10 compounded by the 
myth that stimulants may lower seizure threshold.11  
The purpose of this consensus paper developed by the International League 
Against Epilepsy (ILAE) Pediatric Commission is to provide evidence-based guidance 
to inform clinical practice regarding screening, diagnosis and management of ADHD 
in pediatric epilepsy patients. 
 
METHODS 
A Task Force on Pediatric Comorbidities was recruited by the Pediatric 
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Commission of the International League Against Epilepsy (ILAE). The working group 
identified 5 specific questions which were highly relevant to clinical care (Table 1), and 
for each, a group of 3-4 members reviewed the existing literature.  
The systematic review was completed, for each study question using a National 
Library of Medicine and Embase search with focused search terms (supplemental 
data, Table S1). The process followed PRISMA requirements (Table S2) and  was 
registered on PROSPERO (registration number CRD42018094617) (Table S3). The 
literature search was performed with a date-range spanning January 1990 to January 
2018. Only papers in English were considered. Supplemental table S1 provides more 
detail on the specific study question related search terms and the number of studies 
identified.  Where possible, recommendations were graded according to level of the 
evidence-based data according to the American Academy of Neurology Practice 
Parameter (supplemental data, Table S4).12 Where there were single studies which 
related to the study question, the class (I, II, III, IV) of the study rather than a grade 
(A,B,C,U) was documented. Where consistent evidence was lacking but a 
recommendation remained useful, level U category was implemented, and the 
working group acknowledged that this was their expert opinion. Formal workshops to 
synthetize the literature search, and to discuss grading of evidence and “expert 
opinion”, were organized by the ILAE pediatric commission during the International 
Epilepsy Congress in Turkey 2015 and the American Epilepsy Society meeting in 
2016, in addition to regular informal communications amongst each sub-question 
working group.   
 
RESULTS 
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An executive summary is presented in Table 2. The full document reports the 
available data and the group agreement question by question. 
1. What are the risk factors for ADHD in children and adolescents with epilepsy 
and when should screening begin? 
What are the risk factors of ADHD in children with epilepsy?  
There is a bidirectional association between epilepsy and ADHD, with ADHD occurring 
2.54 times more commonly in children with epilepsy than in control children without 
epilepsy, and epilepsy occurring 3.94 times more in children with ADHD than in control 
children without ADHD.5  
Discussion of Findings (supplemental data Table S1). 
Sex. (Level A) 
In the general population, ADHD is 3-7 fold more common in boys than girls.13 
However, most studies document equal sex distributions of ADHD in children with 
epilepsy.14 Two studies evaluating children with new-onset epilepsy found that male 
sex was not predictive of higher rates of ADHD.14, 15 Similar findings were noted in 
studies of children with pre-existing epilepsy.4,16 In contrast, a single cross sectional 
study investigating the risk of ADHD in patients aged 10-19 years with focal or 
generalized epilepsy found a strong trend between the presence of ADHD and male 
sex (p=0.06).17 In conclusion, most studies found no increased risk in boys with 
epilepsy compared to girls with epilepsy.  
Prenatal insults. 
A single, class I, prospective observational study of children born to mothers on 
monotherapy AEDs  during pregnancy, found that a higher level of inattentiveness and 
hyperactivity in children at 3 years of age with prenatal exposure to valproate, 
compared to carbamazepine, lamotrigine or phenytoin.18  
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Intellectual and Developmental Disabilities. (Level A) 
Class I and II studies consistently note a higher prevalence of ADHD in children with 
associated intellectual and developmental disabilities. A cross-sectional survey of 
British children noted a higher rate of comorbid ADHD in those with complicated 
epilepsy, inclusive of severe learning disorders, speech or language problems.19 In 
children with newly-diagnosed epilepsy, significantly higher rates of school-based 
remedial services and neuropsychological deficits in executive function occurred in 
children with the additional comorbidity of ADHD.14 A study of 85 children with epilepsy, 
found that ADHD was present in only 20% of patients with normal cognitive function, 
versus 59% of those children with cognitive delays.20 A prospective, community-based 
study of children with epilepsy, found that children with intellectual disability had a 
higher mean level of symptoms on both the Parent and Teacher versions of the ADHD-
Rating Scale IV than those without intellectual disability.21 In addition, Reilly and 
colleagues found that developmental coordination disorder was significantly predictive 
of a higher risk of ADHD.22 In conclusion children with epilepsy as well as intellectual 
and developmental disabilities are at increased risk of ADHD. 
Family history of ADHD  
It is generally accepted that genetic factors play a significant role in predisposition to 
ADHD.23 Only one small class III study has evaluated this association in children with 
epilepsy and comorbid ADHD. Sixteen mothers of children with ADHD plus epilepsy 
were evaluated using the ADHD Rating Scale IV, and half met criteria for ADHD.24 
Age at epilepsy onset. (Level U) 
Although some studies show higher prevalence of ADHD amongst those with earlier 
age of epilepsy onset, the literature is conflicted on this topic. Alfstad and colleagues 
demonstrated that early onset of epilepsy increased the risk of developing psychiatric 
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disorders overall, although the study did not specifically address ADHD alone (class 
II).17 Similarly, a study of adolescents with epilepsy attending mainstream schools, 
noted higher rates of ADHD in those with younger age at seizure onset (class II).25 A 
small study on children with childhood epilepsy with centrotemporal spikes(CECTS), 
found that children who were younger at epilepsy onset had higher prevalence of 
attention deficit (class II).26  
In contrast, Hermann and colleagues found no significant correlation between younger 
age at seizure onset and higher rates of ADHD (class II) in a cohort of children with 
newly-diagnosed epilepsy.14 Similarly, Kral and colleagues found no association 
between earlier age at epilepsy onset and ADHD in a retrospective cohort study of 
children with epilepsy (class III).27  
Seizure and epilepsy type. (Level U) 
Several well-designed studies provide evidence that children with childhood absence 
epilepsy (CAE) have high rates of ADHD; however, these studies did not compare CAE 
to other epilepsy types.28-30 Four studies have assessed whether specific seizure types 
correlate with greater risk of ADHD and found no correlation.4, 14, 15, 27 In contrast, one 
study comparing 23 children with temporal lobe epilepsy to 20 children with idiopathic 
generalized epilepsy found that those with temporal lobe epilepsy performed worse on 
tests of attentional control (class III).31 Another study comparing 51 children with focal 
seizures with altered awareness to 31 with CAE found similar prevalence of executive 
dysfunction in both cohorts (class II).32 
EEG Variables (Level U) 
Several studies on small cohorts of children with CECTS noted a correlation between 
higher spike index and poorer function on measures of attention.26, 33 In contrast a 
small pilot study did not find any correlation between spike index during sleep and 
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severity of ADHD symptoms in children with various types of epilepsy.34 A prospective 
study of children evaluated at seizure onset and compared to healthy siblings, found 
that interictal spikes were an independent risk factor of processing speed but not of 
attention/executive/construction impairment.35 In conclusion, there is no convincing 
evidence for a relationship between interictal EEG changes and the severity of 
attention deficits. 
Seizure frequency and control (Level B) 
Most studies support a link between poor seizure control and higher risk of ADHD. In 
a prospective observational class III study of 40 children with “idiopathic or cryptogenic 
epilepsy”, both higher seizure frequency and polypharmacy correlated with  greater 
risk of developing ADHD.36 In a survey of children with drug resistant epilepsy 
attending a regional epilepsy center, higher seizure frequency was correlated with 
greater risk of attention and hyperactivity subscale scores on the Child Behavior 
Checklist (CBCL) (class III).37 In a class III study of 75 children with focal epilepsy, 
those with seizures occurring at least weekly, were rated by their parents to have more 
symptoms of hyperactivity than those having less frequent seizures.38 A study of 
adolescents with epilepsy, found a significant correlation between greater number of 
AEDs used and lower scores on an inattentive subscale (class III).25 
A single class III study reported a prevalence of ADHD of over 60% in a cohort of 
children with refractory epilepsy.16 While this study suggests intractability is highly 
correlated with ADHD, a comparison group with less severe epilepsy was lacking. 
Conversely, a single population-based, case-control study found no significant 
correlation between seizure frequency at initial diagnosis in children with newly-
diagnosed epilepsy (class II).15  
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Based on combined study findings, but balanced by the limitation of most data being 
from class III studies, there is evidence to support an association between poor seizure 
control and increased risk of ADHD. Future studies need to examine the interaction 
effect of polypharmacy and seizure frequency and control, to determine if the increased 
risk for ADHD is related to seizure frequency and control, or the adverse effects of 
polypharmacy. 
 
When to screen children with epilepsy for ADHD. (Level U; expert opinion). 
There are no studies that evaluate when to screen children with epilepsy for ADHD. 
Based on reports that children with epilepsy are at elevated risk of ADHD at the time 
of presentation with their first seizure39 or when epilepsy is first diagnosed,14 screening 
for ADHD should be performed in every child with epilepsy starting at age 6 years, or 
at the time of diagnosis if older than 6 years, and repeated annually. Attention should 
also be re-evaluated after any change of AED. Screening should not be performed 
within 48 hours of a seizure associated with a post-ictal state.  
 
2.  What screening tools should be used, and how should ADHD be 
diagnosed in children and adolescents with epilepsy? 
 Whilst guidelines and consensus statements for assessment of Attention Deficit 
Hyperactivity Disorder (ADHD) exist,40, 41 42 43  the ideal assessment method and how 
to differentiate among subtypes is not defined.  The diagnosis of ADHD should involve 
health practitioners with expertise in ADHD, such as psychologists, child psychiatrists, 
child neurologists and developmental pediatricians (level U: expert opinion). Diagnosis 
of ADHD requires: 1) validated ADHD rating scales from parents and teachers based 
on Diagnostic and Statistical Manual of Mental Disorders – 4th or 5th editions (DSM-IV 
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and -5); 2) rating scale information through parent interview; and, 3) exclusion of other 
causes. Rating scales permit screening to assess ADHD symptoms but no formal 
recommendations state using one tool over the other (supplemental file, Table S5). 
Measures differ in terms of normative populations, availability in languages other than 
English, cost, whether they assess impairment in various areas (school, home, work), 
screening for symptoms other than ADHD, and time required to complete.44  
Six studies met the inclusion criteria with a total of 608 participants with 
childhood onset epilepsy.  Three were ranked as class I,21, 22, 45 two as class II,17, 46 
and one as class III47. Four of the studies21, 22, 45, 46  included diagnostic efficiency 
statistics (e.g., sensitivity, specificity), and one study reported the concordance 
between the screener identification of problematic behavior and a psychiatric 
diagnosis.17 A summary of study findings is provided in Table 3. 
 Three of the studies used the Strengths and Difficulties Questionnaire (SDQ),48 
with two of them reporting data on the Hyperactivity subscale—among other SDQ 
scores,22, 46 and one using the Total score only17. All studies combined both Borderline 
and Abnormal cut-offs on the SDQ as a positive screen for ADHD. More children 
screened positive on parental reporting of the Hyperactivity scale than actually had the 
diagnosis, compared to teachers who  under-identified children who ultimately received 
a diagnosis of ADHD.22 Another study of similar sample size and with similar ADHD 
rate found the sensitivity and specificity of parental report on the SDQ hyperactivity 
subscale to be stronger than the Reilly et al UK study22 at 86.4% and 95%, 
respectively.46 Borderline or abnormal SDQ total scores are highly correlated with the 
presence of a validated psychiatric diagnosis (93,6%), of which ADHD is the most 
common (31.7%).17 Overall, the SDQ had better sensitivity than specificity, suggesting 
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that it can be used as a screener, but that more detailed psychiatric diagnosis should 
follow for those identified at risk. 
 Two of the studies45, 47 used the parent (CBCL) version of the Achenbach 
System of Empirically Based Assessment49. Using three rating scales found specificity 
for the scores above the clinical cut-offs for ADHD, namely the CBCL (85%), the 
teacher version of the Achenbach measure (TRF) (64%) and the Swanson, Nolan, and 
Pelham-IV Questionnaire (SNAP-IV) (81%).50 There was low concordance between 
the information obtained from parents compared to the teachers, because the TRF 
results were normal for a large proportion of patients diagnosed with ADHD by the 
psychiatric evaluation. Hesdorffer and colleagues also used the parent version of the 
Achenbach System (CBCL) in their longitudinal study of cases of a community cohort 
of childhood onset epilepsy.45, 51 Sensitivity for the CBCL at the 9-year assessment 
was 0%, while specificity was 97%.45  The sensitivity and specificity of the CBCL was 
adequate in a small sample of idiopathic epilepsy patients and comparable to the 
SNAP-IV, but the CBCL was a poor screener when compared against an ADHD 
diagnosis based on a structured interview at a 9 year follow up.   
 A study using the ADHD-Rating Scale IV found significantly higher scores on 
parent versus teacher ratings on all three subscales (total score, inattentive score, and 
hyperactive-impulsive score).21  Using the 80th percentile cutoff, sensitivity and 
negative predictive values were higher for parent reports but specificity and positive 
predictive values were higher for teacher responses.  
Given the limited number of studies that met criteria, additional research is 
needed.  Nonetheless, one class I and two class II studies support the ability of the 
SDQ to predict ADHD diagnosis in children with epilepsy (Level B).  These three 
studies had relatively larger sample sizes (>65), included a wide age range, 
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represented diverse epilepsy types, and were from different countries. The SDQ is 
available at no cost in multiple (>80) languages and has ability to screen for other 
problems.  Potential drawbacks of the SDQ include lower sensitivity for the inattentive 
presentation of ADHD,52, 53 which is often more prevalent in epilepsy populations.14, 16, 
54
 However, this weakness was not reflected in the studies reviewed here where the 
combined subtype was more prevalent and thus may be contributing to the strong 
ability of the SDQ to perform well. The low specificity of the SDQ could be a limitation; 
but, as a screening tool, that limitation can be remedied by appropriate follow up with 
a diagnostic interview by a qualified clinician. It is more important to over identify (false 
positive) on screening rather than miss children (false negative) who are at risk (level 
U; expert opinion). Other limitations of the SDQ, as well as other measures, may be its 
utility in different sub-populations who have epilepsy including children with intellectual 
disability 55, 56 or of different racial and ethnic backgrounds57.  Overall very few 
measures evaluating children for a diagnosis of ADHD are validated (nor do they have 
generated scoring or cut-off norms) for populations from different ethnic or cultural 
backgrounds or those with intellectual disability. 
Results are limited to questionnaires. There is also good rationale for using a 
multi-trait, multi-method approach which includes a short computerized evaluation.58  
Continuous Performance Tasks (CPTs) have high positive predictive value but poor 
negative predictive value meaning that a child that performs poorly is likely to have 
ADHD but a child who “passes”, may also still have ADHD; thus, computerized tests 
do not reliably differentiate children with ADHD from those without.59, 60  CPTs that rely 
on reaction time may also be a challenge as children with epilepsy have slow 
processing speed which may interfere with performance rather than a primary attention 
problem.38 Access to free cognitive functioning tools in children with epilepsy is 
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available but these need to be assessed for sensitivity and specificity.61 One such tool 
is EpiTrack Junior which is a screening tool to assess attention and executive function 
validated in German and Austrian cohorts.61 The tool has not yet been tested for its 
reliability in predicting ADHD. 
 
3. What criteria can be used to distinguish ADHD from other conditions such as 
absence seizures, learning disorders and other conditions that mimic ADHD? 
ADHD may be misdiagnosed in children with absence epilepsy and vice versa.62 
Further ADHD is a common co-morbidity in children with absence seizures, occurring 
in 30-60% of affected cohorts.28  
Studies reporting the clinical aspects to make the distinction between ADHD and 
absence epilepsy were scarce. Three features were more suggestive of non-epileptic 
staring than absence seizures: (1) lack of interruption of play; (2) more commonly 
noted by a professional rather than a parent; and, (3) interruptible by external stimuli, 
such as touch.63 Furthermore, hyperventilation induces an absence seizure in most 
children with untreated childhood absence epilepsy.64 Comparing 17 children with CAE 
to 27 with ADHD, 2 items, “does not complete homework” and “does not remain on 
task”, were found which had a 79% sensitivity and 92% specificity for ADHD.62 Lee 
and colleagues found that commission errors (number of responses to non-targets) 
and response time variability was increased in children with ADHD and CAE, 
compared to those with CAE alone.29 Differing study methodologies limited 
comparison.  In conclusion, a distinction between ADHD and CAE should be based on 
history and an EEG with hyperventilation (level U, expert opinion).  
 
Approximately 21-33% of children with epilepsy have comorbid intellectual disability.65-
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67
 Furthermore, even in those with normal IQ, learning disabilities are common.68 It has 
already been documented that intellectual disability is correlated with higher risk of 
ADHD (see Section 1: Intellectual and Developmental Disabilities, above). Similarly, 
sleep disorders are more prevalent amongst children with epilepsy and comorbid 
ADHD compared to those with epilepsy alone.69 Both learning and sleep disorders may 
present as staring and inattention. Formal cognitive testing should be strongly 
considered in children with epilepsy who are struggling at school (Level U: expert 
opinion). Careful screening for anxiety and depression, as well as bipolar disorder and 
early onset schizophrenia, and queries regarding sleep should be undertaken routinely 
in children with epilepsy, particularly if inattention and academic concerns are present 
(level U: expert opinion). Where the child neurologist is unable exclude these 
disorders, psychologist or psychiatric evaluation using screening instruments should 
be implemented.  
 
4.  What is the recommended management of ADHD in children and 
adolescents with epilepsy? 
Are there some precautions to consider with certain AEDs with regards to 
ADHD? 
Sixteen studies were identified (supplemental data, Tables S1, S6 with additional 
references). 
There were 3 class I studies. 70-72  Study populations reviewed were CAE and focal 
seizures treated with various AEDs.70, 71 The two studies reviewing ethosuximide, 
lamotrigine and valproate in CAE provided strong evidence that valproate is associated 
with exacerbation of attentional issues in this population.70, 71 The other study 
compared levetiracetam to placebo in children with focal seizures, and showed 
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marginal improvement in behavior, but not specifically attention in those treated with 
levetiracetam.72   
There were 2 class II studies, one assessed focal seizures and the other children with 
CECTS. 73, 74 The focal seizure study reported that children on monotherapy or 
combined therapy with carbamazepine, oxcarbazepine or sodium valproate had no 
significant difference in combined processing speed and attention, as secondary 
outcomes, but was limited by a short study period.73 The other study reviewed 
topiramate and carbamazepine in children with CECTS.74 The topiramate group had a 
trend towards improvement in attention but worsened cognition, compared to those on 
carbamazepine, however the lack of significance of these findings limited further 
conclusions. 
There were 11 class III studies. Two studies reviewed CECTS, one focal seizures, one 
generalized seizures, one complex seizure disorders and six all seizure types. Diverse 
AEDs were included with little consistency across studies limiting comparison. 
Polytherapy was associated with higher rate of behavioral problems. (level C). Several 
studies from both resource-poor and resource-equipped settings found no correlation 
between AEDs and behavior and attention problems. A Tanzanian based study found 
no evidence of behavior exacerbation with AEDs, including phenobarbital, but 
assessments were based solely on parental feedback and access to AEDs was limited 
with only 48% of the study group receiving therapy 75.  This is supported by studies 
from resource equipped settings as well. In contrast, other studies reported that 
patients with CECTS on AEDs were more likely to have social problems, aggressive 
behavior, and attention problems, and be anxious / depressed.76 The study group 
alluded that this finding was related to ongoing seizures rather than specifically AEDs. 
Another study concluded that topiramate was associated with worsening in behavior 
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in children with epilepsy aphasia syndromes at 3 months, but this was much less 
marked at 6 and 12 months of intervention time.77  
Should precautions be considered with specific AEDs with regard to ADHD? 
(Table S7 with additional references). There was strong evidence (level A) to support 
the finding that valproate can exacerbate attentional issues in children with CAE. 
Polypharmacy is more likely to be associated with behavioral problems than 
monotherapy (level C). Studies are needed to elucidate whether the polytherapy itself 
has resulted in the behavioral problems, or the combination of polytherapy and the 
underlying brain problem reflects difficult-to-control epilepsy which, in turn, has 
resulted in the prescription of polytherapy. As such polytherapy has not been proven 
to cause of behavioural problems but is a marker for the complication.  Data to support 
adverse behavioral effects from phenobarbital, whilst reported, is inconsistent and 
lacking good quality evidence due to small study sizes, lack of accepted behavioral 
screens and poor consistency in study methodologies. More studies with one epileptic 
syndrome comparing AEDs are necessary.  
 
Do methylphenidate, atomoxetine or amphetamines have a worsening 
effect in seizure frequency? (Table S6, S7) 
Exacerbation of seizures is reported in 0-18% of study populations on 
methylphenidate, but most are mild and transient, with no more than 5% stopping 
medication. Since these studies were not placebo-controlled it is not possible to 
determine if the changes are related to baseline fluctuations. Seizure exacerbation 
rates for atomoxetine were 7-9% but again the numbers were too small to draw 
conclusions, and there are no data for amphetamines. Seven studies which included 
patients with refractory epilepsy, indicated that methylphenidate is probably safe. 
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There was only one study which documented tolerability to atomoxetine in a complex 
population group, 7% had seizure exacerbation.78 Data collected by the 
pharmaceutical manufacturer, found that seizures were no more prevalent in children 
with ADHD treated with atomoxetine than in children with ADHD without 
psychostimulant intervention.79 This data did not separate out children with co-morbid 
epilepsy. 
 
Are there any evidence-based treatment recommendations with respect to 
the management of ADHD in children and adolescent with epilepsy? 
Data relating to treatment of ADHD in children and adolescents with epilepsy is limited 
(Table S7). There are no class I studies on efficacy and only seven class II and eight 
class III studies. For tolerability only nine class II and nine class III studies  were 
identified. Most available data are on methylphenidate (n=16), with very limited data 
addressing amphetamines (n=1) or atomoxetine (n=2). Three studies involved adult 
patients. Lack of consistency in study methodology limited comparison between 
studies. For methylphenidate, overall there was a 65-83% improvement in ADHD 
symptoms of affected patients with co-morbid epilepsy, with statistical significance 
identified in several papers. Atomoxetine and amphetamines may be less effective, but 
data are too limited to draw conclusions. One adult based class III study comparing 
response to methylphenidate versus amphetamines found greater efficacy in the 
methylphenidate group.80 Two class III and one class IV study reviewed response to 
atomoxetine in a pediatric population with epilepsy and ADHD, 59% and 82% reported 
benefit with the remaining study reporting that 37% continued therapy but actual 
efficacy was not quantified.78, 81, 82  
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In conclusion, Level B evidence supports efficacy of methylphenidate in children with 
epilepsy and comorbid ADHD. There is level U evidence for efficacy of atomoxetine 
and amphetamines. For tolerability, safety of methylphenidate in children with epilepsy 
(both controlled and refractory) and ADHD, is supported by Level B evidence, 
atomoxetine is level C and amphetamine level U.  
Class I studies are needed to confirm these recommendations.  
 
5. What is the recommended follow-up and transition of children and 
adolescents with ADHD and epilepsy? 
• When and how to discontinue pharmacological treatment of ADHD in 
children and adolescents with epilepsy 
There are no studies that focus specifically on the natural history of ADHD in children 
and teens with epilepsy. Thus, there is no data to inform decisions regarding need for 
maintenance of pharmacological treatment for ADHD in such cohorts.  
 
However, in approximately two-thirds of cases with ADHD alone, symptoms persist 
into adulthood.83 ADHD is often associated with other comorbidities including 
substance abuse and mood disorders, and lack of symptom management at this critical 
time in adolescence and young adulthood which may have profound consequences on 
academic and vocational performance, social relationships and risk-taking behavior. 
Furthermore, young adults with ADHD may not appreciate, and therefore not seek care 
for their symptoms, or may stop stimulants as they perceive they have outgrown this 
disorder.83 
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Thus, if pharmacological treatment of ADHD is beneficial and appears well tolerated, 
it may be continued for as long as it remains effective, but should be reviewed annually, 
as recommended by ADHD clinical guidelines (class IV). 42  
 
• What is the ideal management of transition of care to the adult services? 
There were no studies devoted to transition of patients with both comorbid ADHD and 
epilepsy. But various guidelines for transition of care for adolescents with special 
needs exist.84 (Supplemental data: Table S8).  
 
A transition working group comprising pediatric and adult health care providers and 
patient representatives identified seven steps to maximize a successful transition 
(Table S8) and highlighted psychiatric issues such as ADHD as a factor which may 
increase the risk of unsatisfactory transfer.85 Another report from the Transition in 
Epilepsies symposium identified ADHD as a treatable disorder which may interfere 
with transition and successful adulthood.86   
 
The NICE guidelines for transition of adolescents with ADHD were established in the 
UK in 2008,42 and accepted throughout Europe (class IV), and specific 
recommendations are listed in Table S6. Treatment of ADHD declines sharply from 
childhood through young adulthood despite persistence of functional impairment. 
Primary care providers are less likely than pediatricians or psychiatrists to prescribe 
medications for ADHD.83  
Recommendations (Level U: expert opinion)83, 87 include multidisciplinary involvement 
in transition and adult ADHD clinics. This is essential as many patients experience 
challenges with housing, employment, relationships and psychosocial well-being. 
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CONCLUSION 
This paper addresses the common and challenging clinical aspects of managing 
children with epilepsy and ADHD. Key study questions on common and practical 
issues were identified and the evidence in the literature critiqued to establish the 
strength of evidence to support statements and where possible to put forward 
recommendations (Table 2).  
Despite ADHD being a common comorbidity for children with epilepsy,5 the analysis 
was limited by the lack of class I studies, consistency across study methodology and 
directness to the study questions. Specifically there was lack of controlled, randomized 
double blind studies, of large sample and follow-up, lack of specific evaluation of 
attention, inadequate data on impact of each AED on attention, and study cohorts of 
broad, phenotypic heterogeneity. Few studies used a neuropsychological battery to 
evaluate attention. Those studies that did use appropriate batteries (e.g, Masur et 
al.),70 in general, used one instrument. In the case of Masur and colleagues, 
Continuous Performance Test (CPT) was used, which is regarded as the gold standard 
tool for sustained attention. Some studies used the CBCL which is based on parents’ 
report and does not replace neuropsychological testing.  
Young children with suspected ADHD should be screened for psychiatric diagnoses 
that might mimic ADHD in particular anxiety disorders that are co-morbid with pediatric 
epilepsy. 
Impulsivity is one of the core features of ADHD, but this symptom is not well studied in 
children with co-morbid epilepsy. The most common form of ADHD in children with 
epilepsy is the inattentive form, with the result that there is limited data on impulsivity.4 
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The report was useful to identify where common management concepts were not 
supported by strong evidence base and where there are significant areas in need of a 
more structured and targeted research.  
This report has been generated to provide a practical but evidence-based guide to 
challenging areas in the approach to the care of children with epilepsy who are at risk 
of, or affected by, the co-morbidity ADHD. The outcome of this systematic review is to 
demonstrate the need for better designed studies to address many of the important 
areas addressed.   
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Bullet points : 
• Risk factors for ADHD in children with epilepsy include co-morbid 
developmental disabilities, as well as poor seizure control. 
• Data support the ability of the SDQ to predict ADHD diagnosis in children with 
epilepsy 
• Polytherapy is more associated with behavioral problems than monotherapy. 
• Valproate can exacerbate attentional issues in children with CAE. 
• Methylphenidate is tolerated and effective in children with epilepsy and co-
morbid ADHD 
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Table 1: List of clinical practice-oriented questions about ADHD in Children and Teens with 
Epilepsy identified by the ILAE Pediatric Commission  
 
1. What are the risk factors for ADHD in children and teens with epilepsy and 
when should screening begin? 
 
2. What screening tools should be used, and how should ADHD be diagnosed 
in children and adolescents with epilepsy? 
 
3. What criteria can be used to distinguish ADHD from other conditions such as 
absence seizures, learning disorders and other conditions that mimic ADHD? 
 
4. What is the recommended management of ADHD in children and adolescents 
with epilepsy? 
 
5. What is the recommended follow-up and transition of children and 
adolescents with ADHD and epilepsy? 
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Table 2 : Summary of Recommendations with regard to screening, diagnosis and management of ADHD in children with epilepsy.  
 
Study question Recommendation Level of 
recommendation 
Comment 
1. What are the risk factors 
for ADHD in children 
and teens with epilepsy 
and when should 
screening begin? 
   
What are the risk factors 
of ADHD in children with 
epilepsy?  
 
  
 
 
 
 
 
 There is no increased risk of ADHD in boys with epilepsy 
compared to girls with epilepsy.   
A 
 
 
 Valproate use in pregnancy is associated with 
inattentiveness and hyperactivity in offspring.  
Class I 
 
Single class I study 
 
 Children with epilepsy with comorbid intellectual and 
developmental disabilities are at increased risk of ADHD. 
A 
 
 
 Evidence is conflicted for the impact of early seizure onset 
on the development of ADHD in children with epilepsy 
U Need large 
prospective studies  
 Specific seizure types are not predictive of higher rates of 
ADHD 
U  
 Poor seizure control is associated with increased risk of 
ADHD.  
B  
When to screen the 
children with epilepsy 
for ADHD  
Screening for ADHD should be performed from 6 years or at 
the time of diagnosis and repeated annually.  
Reevaluation of attention function after any change of AED 
Screening should not be performed within 48 hours of 
seizure event associate with a post ictal state   
U 
 
U 
U 
 
Expert opinion  
 
Expert opinion 
Expert opinion 
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2. What screening tools 
should be used, and 
how should ADHD be 
diagnosed in children 
and adolescents with 
epilepsy? 
  
 
 
 
 The diagnosis of ADHD should involve health practitioners 
who have undergone expert training in the recognition of 
ADHD.  
 
U 
 
Expert opinion 
 
 Data support the ability of the SDQ to predict ADHD 
diagnosis in children with epilepsy 
 
B Expert opinion – 
research on other 
screening tools is 
needed 
 It is more important to over identify (false positive) on 
screening rather than miss children (false negative) who are 
at risk  
U Expert opinion 
3. What criteria can be used 
to distinguish ADHD from 
other conditions such as 
absence seizures, learning 
disorders and other 
conditions that mimic 
ADHD? 
   
 A distinction between ADHD and CAE should be based on 
history and an EEG with hyperventilation. 
U Expert opinion 
 Formal cognitive testing is strongly recommended in children 
with epilepsy who are struggling at school.  
U Expert opinion 
 Careful screening for anxiety and depression, and queries 
regarding sleep should be undertaken routinely in children 
U Expert opinion 
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with epilepsy, particularly if inattention and academic 
concerns are present.  
4.  What is the 
recommended management 
of ADHD in children and 
adolescents with epilepsy? 
 
   
Are there precautions 
to consider with 
certain AEDs with 
regards to ADHD? 
Polytherapy is more likely to be associated with behavioral 
problems than monotherapy. 
Valproate can exacerbate attentional issues in children with 
CAE. 
C 
 
A 
 
Does methylphenidate 
exacerbate seizures? 
Methylphenidate is tolerated in children with epilepsy (both 
controlled and refractory)  
Limited evidence supports that atomoxetine is tolerated in 
children with epilepsy and ADHD.  
Tolerability for amphetamine in children with epilepsy is not 
defined. 
B 
 
C 
 
U 
 
Is there any 
evidence-based 
treatment to the 
management of 
ADHD in children and 
adolescent with 
epilepsy? 
Evidence supports efficacy of methylphenidate in children 
with epilepsy and comorbid ADHD. 
Limited evidence exists for the efficacy of atomoxetine and 
amphetamines in children with epilepsy and ADHD. 
B 
 
U 
 
5. What is the recommended 
follow-up and transition of 
children and adolescents 
with ADHD and epilepsy? 
 
   
40 
 
 Multidisciplinary involvement in transition and adult ADHD 
clinics is essential as many patients experience challenges 
with housing, employment, relationships and psychosocial 
well-being. 
U Expert opinion 
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Table 3: Summary of the studies with data to assess which screening tools should be 
used in the diagnosis ADHD in children and adolescents with epilepsy 
Study Country Sample Measure Seizure 
characteristics 
DSM diagnosis 
Reilly et 
al. 201422 
UK-South New onset 
epilepsy in 
the 
community; 
IQ>34; 
n=69; ages 
5-15 
SDQ 
Abnormal/Borderlin
e Parent Rating on 
the Hyperactivity 
scale had 
50%/75% 
sensitivity  
1/3 had weekly 
seizures; 2/3 
had no or less 
often 
Consensus of 
psychologist, 
pediatrician, 
psychiatrist based 
on case notes, 
standardized 
screening and 
cognitive 
measures, and 
school 
observations. N= 
28 ADHD (19 
ADHD-C; 9 
ADHD-I) 
Reilly et 
al. 201721 
UK-South Active 
epilepsy in 
the 
community : 
IQ>34, 
n=69, ages 
5-15 
ADHD-RS IV 
Abnormal parent 
total score had 
86% sensitivity and 
51% specificity 
Abnormal teacher 
total score had 
63% sensitivity and 
90% specificity 
1/3 had weekly 
seizures; 2/3 
had no or less 
often 
Consensus of 
psychologist, 
pediatrician, 
psychiatrist based 
on case notes, 
standardized 
screening and 
cognitive 
measures, and 
school 
observations. N= 
28 ADHD (19 
ADHD-C; 9 
ADHD-I) 
Tanabe 
et al. 
201446 
Japan Primary 
clinic;  
severely 
mentally or 
physically 
handicappe
d excluded; 
n=68; ages 
4-17 
SDQ 
Abnormal/Borderlin
e Hyperactivity 
Parent had 86.4% 
sensitivity; 3 
children missed 
and 2 of them had 
ADHD-I 
 
ADHD-RS was 
significantly 
correlated with 
SDQ Hyperactivity 
scale but not 
compared with 
diagnosis 
76% had no 
seizures; 74% 
on 1 AED; 77% 
LRE; 23% 
generalized 
Structured 
interview with 
parents and 
teachers, mental 
evaluation, and 
behavioral 
observation. 
N=22 (32.4%) dx 
with ADHD (14 
ADHD-C; 8 
ADHD-I) 
Alfstad et 
al. 201617 
Norway 
but used 
UK norms 
Consecutiv
e patients 
with a 
hospital 
stay at a 
tertiary 
center; 
IQ<70 
excluded; 
n=101; 
ages 10-19 
SDQ 
Abnormal/Borderlin
e Parent or Self 
Total Score 
Range of 
epilepsy types 
(52% 
focal/48% 
generalized) 
and etiologies; 
but 
occipital/pariet
al focal 
epilepsy 
excluded; 53% 
Kiddie-SADS-PL; 
neuropsychologic
al testing; n=32 
(31.7%) had 
ADHD 
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on 1 AED/ 55% 
had no GTC in 
last 6 months 
Loutfi et 
al. 201147 
Brazil Routine 
neurology 
clinic visit; 
n=30; ages 
6-13 years 
CBCL Attention 
Problems; 82% 
sensitivity; 85% 
specificity 
 
SNAP-IV cut off; 
93% sensitivity; 
81% specificity 
Idiopathic 
epilepsy, well 
controlled 
Clinical Interview; 
n=16 (53.3% had 
ADHD (7 ADHD-
C; 6 ADHD-HI; 3 
ADHD-I) 
Hesdorffe
r et al. 
201445 
USA-
Connecticu
t 
Longitudinal 
study of 
community-
based 
cohort of 
epilepsy 
cases over 
4 years: 
baseline, 9 
year follow 
up; n=163 
CBCL-DSM 
oriented ADHD 
score; 0% 
sensitivity; 96% 
specificity 
Median age of 
onset 6.8 years 
Diagnostic 
Interview 
Schedule for 
DSM-IV 
(DIS-IV); n=13 
(5.4%) had ADHD 
 
 
Table 2 : Summary of Recommendations with regard to screening, diagnosis and management of ADHD in children with epilepsy.  
 
Study question Recommendation Level of 
recommendation 
Comment 
1. What are the risk factors 
for ADHD in children 
and teens with epilepsy 
and when should 
screening begin? 
   
What are the risk factors 
of ADHD in children with 
epilepsy?  
 
  
 
 
 
 
 
 There is no increased risk of ADHD in boys with epilepsy 
compared to girls with epilepsy.   
A 
 
 
 Valproate use in pregnancy is associated with 
inattentiveness and hyperactivity in offspring.  
Class I 
 
Single class I study 
 
 Children with epilepsy with comorbid intellectual and 
developmental disabilities are at increased risk of ADHD. 
A 
 
 
 Evidence is conflicted for the impact of early seizure onset 
on the development of ADHD in children with epilepsy 
U Need large 
prospective studies  
 Specific seizure types are not predictive of higher rates of 
ADHD 
U  
 Poor seizure control is associated with increased risk of 
ADHD.  
B  
When to screen the 
children with epilepsy 
for ADHD  
Screening for ADHD should be performed from 6 years or at 
the time of diagnosis and repeated annually.  
Reevaluation of attention function after any change of AED 
Screening should not be performed within 48 hours of 
seizure event associate with a post ictal state   
U 
 
U 
U 
 
Expert opinion  
 
Expert opinion 
Expert opinion 
2. What screening tools 
should be used, and 
how should ADHD be 
diagnosed in children 
and adolescents with 
epilepsy? 
  
 
 
 
 The diagnosis of ADHD should involve health practitioners 
who have undergone expert training in the recognition of 
ADHD.  
 
U 
 
Expert opinion 
 
 Data support the ability of the SDQ to predict ADHD 
diagnosis in children with epilepsy 
 
B Expert opinion – 
research on other 
screening tools is 
needed 
 It is more important to over identify (false positive) on 
screening rather than miss children (false negative) who are 
at risk  
U Expert opinion 
3. What criteria can be used 
to distinguish ADHD from 
other conditions such as 
absence seizures, learning 
disorders and other 
conditions that mimic 
ADHD? 
   
 A distinction between ADHD and CAE should be based on 
history and an EEG with hyperventilation. 
U Expert opinion 
 Formal cognitive testing is strongly recommended in children 
with epilepsy who are struggling at school.  
U Expert opinion 
 Careful screening for anxiety and depression, and queries 
regarding sleep should be undertaken routinely in children 
U Expert opinion 
with epilepsy, particularly if inattention and academic 
concerns are present.  
4.  What is the 
recommended management 
of ADHD in children and 
adolescents with epilepsy? 
 
   
Are there precautions 
to consider with 
certain AEDs with 
regards to ADHD? 
Polytherapy is more likely to be associated with behavioral 
problems than monotherapy. 
Valproate can exacerbate attentional issues in children with 
CAE. 
C 
 
A 
 
Does methylphenidate 
exacerbate seizures? 
Methylphenidate is tolerated in children with epilepsy (both 
controlled and refractory)  
Limited evidence supports that atomoxetine is tolerated in 
children with epilepsy and ADHD.  
Tolerability for amphetamine in children with epilepsy is not 
defined. 
B 
 
C 
 
U 
 
Is there any 
evidence-based 
treatment to the 
management of 
ADHD in children and 
adolescent with 
epilepsy? 
Evidence supports efficacy of methylphenidate in children 
with epilepsy and comorbid ADHD. 
Limited evidence exists for the efficacy of atomoxetine and 
amphetamines in children with epilepsy and ADHD. 
B 
 
U 
 
5. What is the recommended 
follow-up and transition of 
children and adolescents 
with ADHD and epilepsy? 
 
   
 Multidisciplinary involvement in transition and adult ADHD 
clinics is essential as many patients experience challenges 
with housing, employment, relationships and psychosocial 
well-being. 
U Expert opinion 
 
 
